Repository logo
 

Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.

Published version
Peer-reviewed

Repository DOI


Type

Article

Change log

Authors

Crawford, Abbe H 
Tripathi, Richa B 
Richardson, William D 
Franklin, Robin JM 

Abstract

Oligodendrocyte progenitors (OPs) arise from distinct ventral and dorsal domains within the ventricular germinal zones of the embryonic CNS. The functional significance, if any, of these different populations is not known. Using dual-color reporter mice to distinguish ventrally and dorsally derived OPs, we show that, in response to focal demyelination of the young adult spinal cord or corpus callosum, dorsally derived OPs undergo enhanced proliferation, recruitment, and differentiation as compared with their ventral counterparts, making a proportionally larger contribution to remyelination. However, with increasing age (up to 13 months), the dorsally derived OPs become less able to differentiate into mature oligodendrocytes. Comparison of dorsally and ventrally derived OPs in culture revealed inherent differences in their migration and differentiation capacities. Therefore, the responsiveness of OPs to demyelination, their contribution to remyelination, and their susceptibility to age-associated functional decline are markedly dependent on their developmental site of origin in the developing neural tube.

Description

Keywords

glial diversity, myelin, oligodendrocyte, oligodendrocyte progenitor, remyelination

Journal Title

Cell Rep

Conference Name

Journal ISSN

2211-1247
2211-1247

Volume Title

Publisher

Elsevier BV
Sponsorship
Medical Research Council (MC_PC_12012)
Medical Research Council (MC_PC_12009)
Wellcome Trust (096384/Z/11/Z)
Multiple Sclerosis Society (941)
A.H.C. was funded by a Wellcome Trust Integrated Training Fellowship (096384/Z/11/Z). Work in R.J.M.F.’s laboratory was funded by The UK Multiple Sclerosis Society (941) and by a core support grant from the Wellcome Trust and MRC to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute. Work in W.D.R.’s laboratory was funded by the Medical Research Council (G0800575), the Wellcome Trust (WT100269AIA), and the European Research Council (293544).